Apexigen initiates APX005M Stage 1 clinical trial in adults with solid tumors Apexigen, Inc., a biopharmaceutical firm finding and developing innovative antibody medicines for the treating cancer and various other life-threatening diseases, today the initiation of a Phase 1 clinical trial of APX005M announced, the organization's lead proprietary anticancer program. APX005M is an immuno-activating monoclonal antibody targeting CD40, a receptor that plays a central function in the regulation of antigen demonstration functions and tumor-specific T cell response. The trial is usually a Phase 1, open-label dose-escalation research of APX005M in adults with solid tumors that is intended to create the maximum tolerated dose, the pharmacokinetic profile and the overall safety and tolerability of APX005M.This treatment is an option to long-term anticoagulation and will be especially useful for patients who do not wish the inconvenience of close medical monitoring or the risk of bleeding,’ says Professor Simes. ‘Aspirin will be ideal in the many countries where prolonged anticoagulant treatment is certainly too expensive. A major advantage of this treatment is certainly its cost-effectiveness. Aspirin is normally cheap, but it shall save the treatment costs of the numerous recurrent clots that are prevented. This may mean a saving of millions of healthcare dollars worldwide.’ Co-investigator Tim Brighton, a senior haematologist at Sydney’s Prince of Wales Hospital, adds: ‘This important research demonstrates obviously that low-dosage aspirin reduces the dangers of further blood clot.